In the June issue of Managing Intellectual Property, the publication recognized Finnegan partner Charles E. Lipsey as one of the top ten U.S. litigators in the life sciences patent industry. Representative matters that Mr. Lipsey worked on include University of California v. Eli Lilly and Co., where Finnegan successfully defended Lilly’s human insulin product from infringement allegations, and Eli Lilly & Co. v. Zenith Goldline Pharms, in which Finnegan successfully obtained for Lilly determination of infringement and validity of a patent on the drug product Zyprexa®.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Award/Ranking
U.S. News & World Report Names Finnegan One of the Best Companies to Work For
January 30, 2024
Apple Eyes Long-Term Software Fix for Watch While Appealing Ban
December 28, 2023
Award/Ranking
Asian Legal Business Names Finnegan “International IP Law Firm of the Year”
November 10, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.